Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Manning

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 9, 2025
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final resultsHenriette Farkas, Jonny G Peter, Marcin Stobiecki, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
The Journal of Allergy and Clinical Immunology|March 7, 2026
An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary AngioedemaAleena Banerji, Timothy Craig, Karl Sitz, et al.
The New England Journal of Medicine|September 8, 2010
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedemaBruce L Zuraw, Paula J Busse, Martha White, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 9, 2025
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final resultsHenriette Farkas, Jonny G Peter, Marcin Stobiecki, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
The Journal of Allergy and Clinical Immunology|March 7, 2026
An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary AngioedemaAleena Banerji, Timothy Craig, Karl Sitz, et al.
The New England Journal of Medicine|September 8, 2010
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedemaBruce L Zuraw, Paula J Busse, Martha White, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
Pageof 3